NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Morgan &
Morgan announces that it is investigating potential legal
claims against the Board of Directors of ViroPharma Incorporated
("ViroPharma" or the "Company") (Nasdaq: VPHM) concerning the
proposed acquisition of the Company by Shire plc ("Shire") in a
transaction valued at about $4.2
Billion.
Under the terms of the agreement, public shareholders of
ViroPharma will receive $50.00 per
share in cash for each share of ViroPharma they own.
If you own shares of ViroPharma and want more information
about the merger investigation, please contact George Pressly, Esq. at 1(800)
631-6234 or email George at
AskGeorge@morgansecuritieslaw.com.
Our investigation concerns possible breaches of fiduciary duty
and other violations of law byViroPharma's Board of Directors for
not acting in the best interest of the Company's shareholders in
connection with the sale process.
Morgan & Morgan is one of the nation's largest 200 law
firms. In addition to securities fraud, the firm also practices in
the areas of antitrust, personal injury, consumer protection,
overtime, and product liability. All of the Firm's legal
endeavors are rooted in its core mission: provide investor and
consumer protection and always fight "for the people."
Attorney advertising. Prior results do not guarantee a similar
outcome.
Contact:
Morgan & Morgan
Peter Safirstein, Esq.
28 West 44th Street
Suite 2001
New York, NY 10036
1-800-631-6234
info@morgansecuritieslaw.com
SOURCE Morgan & Morgan